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Abstract
Objective—Hypercortisolemia results in changes of the immune system and elevated infection 
risk, but data on the WBC changes in pediatric Cushing syndrome (CS) are not known. We 
describe the changes of the WBC lineages in pediatric endogenous hypercortisolemia, their 
associations with the markers of disease severity, and the presence of infections.
Study design—We identified 197 children with endogenous CS. Clinical and biochemical data 
were recorded. Sixty-six children with similar age and gender, and normocortisolemia served as 
controls.
Results—The absolute lymphocyte count of CS patients was significantly lower than that of 
controls, while the total WBC and the absolute neutrophil counts were significantly higher. These 
changes correlated with several markers of CS severity and improved after resolution of 
hypercortisolemia. Infections were identified in 35 patients (17.8%), and their presence correlated 
to elevated serum morning cortisol, midnight cortisol, and urinary free cortisol levels, as well as 
with the decrease in absolute lymphocyte count.
Conclusions—Children with endogenous CS have abnormal WBC counts, which correlate with 
the severity of CS, and normalize after cure. Infections are common in this population; clinicians 
should be aware of this complication of CS and have low threshold in diagnosis and treating 
infections in CS.
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Introduction
Since 1948, when glucocorticoids (GCs) were first used for the management of rheumatoid 
arthritis, pharmacologic doses of glucocorticoids have been widely prescribed for their 
immunosuppressive properties.(1, 2) GCs currently constitute the first line therapy for many 
autoimmune, allergic, and malignant disorders, both in adults and in children.(2)
GCs exert various effects on the immune system, affecting both the cellular components as 
well as the proteins of the inflammatory pathway.(3) Specifically, GCs may alter the number 
of the white blood cells, resulting in leukocytosis, neutrophilia, lymphopenia, and 
eosinopenia as well as their function, leading to decreased activity of the natural killer cells.
(4–6) At the same time they also affect the concentration of the pro-inflammatory proteins, 
leading to the decrease of several proinflammatory cytokines, such as TNF-alpha, IL1, and 
IFNγ. (7)
Most of these effects have been reported in animal models or cell lines, while the human 
studies of the effects of GCs usually involve patients with additional underlying diseases. 
Endogenous Cushing syndrome (CS) may serve as a model of the net effects of GCs on the 
human body, and indeed adult patients with endogenous CS have been previously studied 
regarding the effects of hypercortisolemia on their immune system.(8, 9) Endogenous CS 
leads to a significant increase in the WBC and the neutrophil counts, and decrease of the 
lymphocyte count.(8) As a result, increased susceptibility to infections has been identified as 
one of the major morbidity and mortality factors in hypercortisolemic patients.(9) The 
significance of this finding is highlighted in the endocrine society guidelines for the 
management of CS, where a recommendation for prophylactic antibiotic use in the adult 
patients with urinary free cortisol (UFC) levels greater than 5 fold the upper normal limit is 
included.(10)
Despite these recommendations in adults with CS, no prior study has described the changes 
of the immune system in the pediatric CS population. We here aimed to describe these 
changes in a large cohort of pediatric patients with endogenous CS. We also investigated the 
presence of infections and their correlation with markers of severity of hypercortisolemia.
Subjects and methods
Subjects
Through a retrospective chart review, we identified 197 patients diagnosed from 1998 until 
2017 with endogenous CS before the age of 18 years old. The patients were evaluated at the 
Clinical Center of the National Institutes Health (NIH) under the protocols 97-CH-0076, 95-
CH-0059 and 00-CH-0160. Our research was approved by the Eunice Kennedy Shriver 
National Institute of Child Health and Human Development (NICHD) Institutional Review 
Board. Written informed consent was obtained from the parents of the minor patients, and 
assent from the minor patients.
The diagnosis of CS and the classification of the various etiologies was based on previously 
described criteria.(11) The diagnosis was confirmed histologically after surgery for all 
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patients that underwent surgical resection. For two of the patients with Cushing disease 
(CD), who underwent surgical treatment at an outside institution, review of the pathology 
report confirmed the presence of a corticotroph adenoma. Of the 38 patients with CS due to 
adrenal causes, 17 patients had confirmed clinical and genetic diagnosis of Carney Complex 
syndrome, while of the patients with CD, two patients had Multiple Endocrine Neoplasia 
(MEN) syndrome type 1, and one patient had tuberous sclerosis.
Sixty-six children, with similar age and gender distribution as our patient cohort, who were 
referred to our institution for evaluation of possible hypercortisolemia and were found to 
have normal cortisol secretion, served as the control group. Most of these patients were 
obese, while some of them had additional pathologic disorders identified: diabetes insipidus 
(n=1), connexin 26 defect and deafness (n=1), fragile X (n=1), hypothyroidism, on 
replacement therapy and biochemically euthyroid at the time of the test, (n=2), MEN 
syndrome type 1 (n=1), developmental delay and learning difficulties (n=2), Kallman 
syndrome (n=1), precocious puberty (n=1), and premature adrenarche (n=1).
Demographic (age, gender, duration of disease), clinical (operation notes, pathology reports, 
presence of infection), hematology and biochemical data (CBC with differential, serum and 
urine cortisol, plasma ACTH) were retrieved from the electronic medical record system. The 
first CBC with differential at the time of diagnosis was used for further analysis. The results 
from the CBC with differential done at the follow up visit closest to 1 year after treatment 
were used for the analysis after cure (mean time to follow up visit 14.1 ± 11.6 months). 
Serum cortisol and UFC results were documented for all the patients at the follow up visit to 
document the resolution of hypercortisolemia.
The average of the first three urinary free cortisol levels was calculated and is referred to as 
UFC. Urinary samples that were collected on days of additional tests, such as 
dexamethasone suppression test, were excluded. Morning cortisol refers to the average value 
of the 7:30am and 8:00am samples of serum cortisol, while midnight cortisol refers to the 
average value of the serum cortisol at 11:30pm and 12:00am. Plasma ACTH refers to the 
average value of 7:30am and 8:00am levels if available, or the plasma ACTH level collected 
closer to 8:00am.
CBC, serum and urine markers of CS
CBC with differential was measured using the Sysmex XN 3000 automated hematology 
system (Lincolnshire, IL). The serum cortisol was measured via Solid-phase, competitive 
chemiluminescent enzyme immunoassay on Siemens Immulite 2500 analyzer, (Malvern, 
PA). UFC (average of the first three samples collected after admission) was measured in 24-
hour urine collections via High Performance Liquid Chromatography/ Tandem Mass 
Spectrometry (LC-MS/MS). The plasma ACTH was measured via chemiluminescent 
enzyme immunoassay on Siemens Immulite 200 XPi analyzer (Malvern, PA).
Statistical analysis
The results are presented as frequencies and percentages, and mean (± standard deviation, 
SD). Data were assessed for distributional normality, and non-parametric tests were used for 
non-normally distributed data. Continuous data were compared between groups (e.g., CS vs 
Tatsi et al. Page 3
Pediatr Res. Author manuscript; available in PMC 2018 June 06.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
controls; CS with infection vs CS without infection) using the two-sample t-test or Wilcoxon 
rank-sum test, as applicable; paired continuous data (e.g., diagnosis vs cure) were compared 
using the one-sample t-test or Wilcoxon signed-rank test. Categorical data between groups 
were compared by means of the χ2 or Fisher’s exact tests, as appropriate, and paired data 
were compared using the McNemar’s test. Correlation analyses utilized the Spearman’s rank 
correlation coefficient. Data were considered statistically significant if the resulting p value 
was < 0.05. Analyses were carried out using SAS v9.4 (SAS Institute, Inc, Cary, NC).
Results
Characteristics of the patients
The clinical and biochemical characteristics of the patients are shown in Table 1. The mean 
age at presentation was 12.5 years, with a range from 2.7 to 18 years of age. There were 
more female than male patients (n = 109, 55.3%). In the control group, there were 66 
individuals, with mean age of 12.5 years (range 2.9 to 17.9 years), and 37 (56%) females. 
The mean duration of disease was 2.6 ± 1.8 years. At diagnosis, the mean morning serum 
cortisol level was 20.4 ± 13.5 mcg/dL, the mean midnight serum cortisol level was 18.6 
± 13.2 mcg/dL, and the mean UFC level was 399 ± 1465 mcg/24H. Most of the patients 
were diagnosed with CD (n = 154, 78.2%), while 38 patients (19.3%) had ACTH-
independent CS due to adrenal causes, and 5 patients (2.5%) were diagnosed with CS due to 
ectopic ACTH production, which is consistent with the previously described relative 
frequency of the various etiologies of CS in children.
All the patients with CD underwent transphenoidal resection (TSS), while the patients with 
adrenal dependent CS underwent unilateral (n = 10) or bilateral (n = 28) adrenalectomy 
according to their underlying disease. Of the 5 patients with ectopic CS, previously reported 
in a separate case series(12), all patients underwent resection of the source of ectopic 
ACTH/CRH production (bronchogenic carcinoma = 1, metastatic pancreatic neuroendocrine 
tumor = 2, thymic carcinoid = 1, metastatic hepatic neuroendocrine tumor = 1), while 
additional therapeutic interventions were implemented depending on the persistence of their 
disease. Of the patients who were followed after surgery (n = 163, 82.7%), 142 patients 
(87.1%) had persistent remission of CS at their latest follow up, 13 patients (8.0%) had 
recurrence of CS after initial remission, and 8 patients (4.9%) were not cured after surgery, 
resulting in a total of 21 patients (12.9%) with persistent or recurrent hypercortisolemia 
during any follow up (Figure 1).
Comparison of the total WBC count and the various cellular components of the immune 
system between the patients with CS and the control group
The total WBC count and the count of the various WBC types of the children with CS were 
significantly different from the corresponding values of the control group. The patients with 
CS had significantly lower absolute lymphocyte count (2.19 ± 0.78 K/mcL) compared to the 
control group (2.55 ± 0.84 K/mcL, p = 0.002). Additionally, they had significantly higher 
total white blood cell count (9.64 ± 2.84 K/mcL vs 7.62 ± 1.78 K/mcL, p < 0.001) and 
absolute neutrophil count (6.42 ± 2.57 K/mcL, ± 2.57, vs 4.22 ± 1.43, p < 0.001) compared 
to the control group. When taking into account the age and gender specific normative cut-off 
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values, 6.1 % of our patients were lymphopenic at diagnosis compared to 1.5 % of the 
control group (not statistically significant, p = 0.19), while leukocytosis and neutrophilia 
were more prevalent in the CS population (45.7 % and 34.7 %, respectively) compared to the 
control population (18.2 % and 9.1 %, respectively p < 0.001 for both).
Comparison of cellular components of the immune system before and after resolution of 
hypercortisolemia
For the patients who were followed after surgery (n = 163), total WBC count was available 
for 136 patients while complete CBC with differential was available for 126 of them. 
Comparison of the WBC count and the count of the various WBC types before treatment 
and after resolution of hypercortisolemia revealed significant improvement of all the WBC 
lineages. Specifically, the absolute lymphocyte count increased significantly from 2.15 
± 0.78 K/mcL at diagnosis to 2.88 ± 1.04 K/mcL after cure (p < 0.001). The total white 
blood cell count decreased from 9.31 ± 2.55 K/mcL at diagnosis to 6.83 ± 1.88 K/mcL after 
cure (p < 0.001), while the absolute neutrophil count decreased from 6.16 ± 2.34 K/mcL at 
diagnosis to 3.25 ± 1.5 K/mcL after cure (p < 0.001) (Table 2). When taking into account the 
age and gender specific normative cut-off values, most patients with abnormal counts at 
diagnosis subsequently normalized at their follow-up visit [90.0% with previous 
lymphopenia (p = 0.035), 91.1 % with leukocytosis (p < 0.001), and 86.8% with neutrophilia 
(p < 0.001) normalized]. When studying specifically the patients who had persistent or 
recurrent disease, the various counts showed temporary improvements at the period of 
remission of CS, with recurrence of several of the changes upon return of hypercortisolemia, 
as described in Table 2.
Correlation of the WBC changes with the markers of CS severity
Several makers of Cushing severity, including the urinary free cortisol (UFC), the morning 
serum cortisol and the midnight serum cortisol, correlated with alterations of the WBC and 
the WBC types at diagnosis. Specifically, the absolute lymphocyte count was negatively 
correlated with the morning and midnight cortisol levels (rs = −0.21, p = 0.004 and rs = 
−0.18, p = 0.011, respectively) and the UFC (rs = −0.16, p = 0.026). Conversely, the absolute 
neutrophil and the total WBC counts were positively correlated with some of the above 
markers (Figure 2). When investigating specifically the patients with CD, the level of 
morning plasma ACTH was not related to immune cell counts (p > 0.05 in all correlation 
analyses with the total WBC, absolute lymphocyte, and absolute neutrophil count). 
Although there were few patients with significantly elevated cortisol levels that could 
potentially influence the statistical analyses, the results remained significant for all the above 
analyses after excluding them.
Presence of infections in children with endogenous CS
In order to assess the clinically significant outcome of the above changes, we identified the 
patients who had reported a significant infection (prolonged duration, persistent after one 
course of treatment, or opportunistic infections) within the 6 months prior to diagnosis, or 
perioperatively. We identified 35 patients (17.8%) who fulfilled the above criterion. Most of 
the infections were fungal infections of the skin and mucosa. Specifically, 24/35 patients had 
evidence or history of prolonged fungal infections (tinea corporis, tinea capitis, tinea pedis 
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or vaginal candidiasis). In addition, bacterial and viral skin infections, sinusitis, urinary tract, 
IV line, and GI infections were also reported. Notably, we did not identify any opportunistic 
infections or any case of sepsis in our cohort.
Correlation of WBC changes with infections and severity of CS
There were remarkable differences between the group of CS patients with a concurrent 
infection and the remaining patients with CS. Specifically regarding the CBC changes, the 
absolute lymphocyte count was significantly lower in the group of patients with infection 
(2.01 ± 0.93 K/mcL) compared to those without (2.24 ± 0.74 K/mcL, p = 0.047). 
Additionally, the patients with infection had significantly higher serum morning cortisol 
(24.4 ± 13.9 mcg/dL, vs 19.6 ± 13.3 mcg/dL, p = 0.008), midnight cortisol (23.3 ± 14.7 
mcg/dL, vs 17.6 ± 12.6 mcg/dL p = 0.005), and UFC levels (426 ± 487.5 mcg/24H, vs 393 
± 1603.4 mcg/24H, p = 0.009) (Figure 3).
Discussion
We report for the first time that children with endogenous hypercortisolemia have significant 
changes in the cells of their immune system, including decreases of the absolute lymphocyte 
count and an increase of the total WBC and the absolute neutrophil count, which correlate 
with the serum and urine cortisol levels. The WBC count changes normalize after the 
resolution of hypercortisolemia, and return upon recurrence of the CS. We also demonstrate 
that the presence of infections, as the clinically significant outcome of these changes of the 
immune system, is significantly associated with the changes of the WBC counts and the 
indices of severity of CS.
Children with endogenous CS may be considered as the human model of the net effect of 
pharmacologic doses of GCs on the immune system. Several of the previous studies have 
described these effects in patients receiving GCs secondary to an underlying disease, such as 
an autoimmune, malignant, or atopic disorder.(13–16) However, these patients may already 
have a dysregulation of their immune system and are frequently on multiple other 
therapeutic agents. Furthermore, the alterations of the immune system in endogenous CS 
have only been studied in the adult population, where additional age related illnesses may 
often be present.(8, 17–19) On the contrary, children with endogenous hypercortisolemia, 
rarely have other comorbidities; thus, it is highly possible that the identified changes are the 
direct effect of the glucocorticoid excess. Children also exhibit continuous growth with 
increased plasticity, and the information that we get from diseases that present in this age 
could provide indirect insight on the adaptation of their immune system.
Given the high prevalence of childhood obesity, where almost one third of children and 
adolescents currently fall under the category of overweight or obese, it is of utmost 
importance to emphasize the signs that can be used by physicians to distinguish those 
individuals who require further workup for CS. (20) One of the main findings of pediatric 
CS is the evidence of weight gain with concomitant height deceleration, which is not present 
in growing obese patient where height acceleration and tall stature are usually observed.(21, 
22) However, other typical findings of CS, such as striae, hirsutism, acne, acanthosis 
nigricans, myopathy, hyperglycemia, hyperlipidemia, and decreased bone mineral density, 
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can sometimes be also seen in obese patients or they develop over a prolonged period of 
hypercortisolemia, when complications have already occurred or treatment becomes 
challenging.(11, 23–25) Although we cannot conclude anything about the timing of the CBC 
changes from our study (since the CBC we analyzed here was obtained after an estimated 
mean duration of disease of 2.6 years), it has been previously described that the changes of 
the WBC counts occur soon after the administration of GCs.(15, 26, 27) Thus CBC with 
differential, which is a low cost, minimally invasive and easy to interpret test, could 
potentially serve as a screening tool for CS in this population, although in the setting of an 
infection this should be interpreted in the context of additional clinical signs. A new study 
ought to look at the timing of this change and see if this test could serve for ruling in or out 
CS among children with obesity.
Additionally, the presence of a persistent or difficult to treat infection should prompt further 
workup for hypercortisolemia in suspicious patients. It is described in the literature that CS 
is associated with increased risk of infections.(28) In a metanalysis by Stuck et al, 
administration of GCs resulted in increased risk of infections in a dose dependent pattern.
(29) Increased infection risk has been also identified as a feature of adults with endogenous 
CS.(30) (31) In the pediatric population, we confirmed the high frequency of infections; 
thus, the presence of an abnormal CBC, with low lymphocytes and high neutrophils, and the 
identification of a persistent infection in an obese child should indicate the need for further 
evaluation.
However, the majority of the infections in our cohort were mild, mostly fungal skin or 
mucosal infections, while invasive or opportunistic infections were not noted to have 
occurred. As we described, the presence of infection is positively associated with the serum 
and urinary cortisol levels. Given the rarity of ectopic CS in childhood, which is known to 
result in significant hypercortisolemia, the lower expected blood and urine levels of cortisol 
could potentially explain the milder nature of the reported infections. This is in accordance 
with the adult population studies, where many of the severe infections have been described 
in patients with ectopic/paraneoplastic CS.(9, 31–33) However, this cannot exclude the 
possibility of a severe infection even in the pediatric population. Indeed, as previously 
reported by Gkourogianni et al, pediatric CS is a potentially fatal condition. Of the four 
deaths reported in that study, at least two of them were attributed to severe infections.(34)
The resolution of the WBC lineage changes after treatment of CS is also important for the 
follow up and counseling of the patients. Although there are reports of continuous immune 
dysregulation, even after normalization of the cortisol levels, most of the previous studies 
have documented a rebound reactivation of the immune system, presenting for example with 
an increased incidence of autoimmune diseases.(35, 36)
To our knowledge, this is the first study to investigate the WBC changes in pediatric patients 
with endogenous CS. One of the main strengths of the study is the large number of patients 
included, especially when considering the rare nature of the disease, since we serve as an 
international center for management of pediatric pituitary tumors. We were also able to 
follow most of the patients longitudinally after treatment, and thus document the 
improvement of the cells of the immune system after cure. A limitation of the study is the 
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retrospective nature of the investigation. Thus, since the timing of the collection of the CBC 
at the time of diagnosis and at the follow up was indicated by our protocol, it cannot be 
informative for the specific timing of the various WBC changes or their resolution. 
Furthermore, we relied on the review of the medical records to document the history of 
infections, which may be underestimated. Additionally, blood samples were not available to 
perform further diagnostic tests, such as lymphocyte phenotyping to detect the specific 
lymphocyte subtype changes, or evaluation of other inflammatory proteins and cytokines, in 
order to assess the changes of the secretory function of the immune cells. As it is known that 
the effect of GCs is not solely the effect on the number of the WBC cells, but also and, 
maybe even more importantly, on their function, further studies are required to describe 
these changes in pediatric endogenous CS.
In conclusion, pediatric patients with CS present with significant changes of the WBC 
counts, including decrease of the absolute lymphocyte count, which normalize after cure and 
return upon recurrence. These changes correlate with the morning and midnight cortisol 
levels and the UFC. The patients with lower lymphocyte count and higher cortisol levels, 
have higher risk for infections, and although most of the infections are mild, the possibility 
of a life-threatening infection cannot be excluded. These findings should be considered as 
part of the phenotypic presentation of patients with CS and may serve as diagnostic clues 
when an obese patient is evaluated for an underlying pathology.
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Figure 1. 
Flowchart of the disease course of pediatric patients with Cushing syndrome (CS).
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Figure 2. 
Scatterplots of the total WBC (a, b, c), absolute lymphocyte (d, e, f), and absolute neutrophil 
count (g, h, i), and their correlations with UFC (a, d, g), morning serum cortisol (b, e, h), and 
midnight serum cortisol (c, f, i) levels. Asterisk (*) indicates p < 0.05.
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Figure 3. 
Boxplot diagrams of the total absolute lymphocyte count (a), morning serum cortisol (b), 
midnight serum cortisol (c) and urinary free cortisol level (d) of the patients with infection 
compared to those without. All values were significantly different (p < 0.05) between the 
two groups (*).
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Table 1
Clinical and biochemical characteristics of pediatric patients with Cushing syndrome.
Characteristic Value
N=197
Mean age at diagnosis, years (± SD) 12.5 (± 3.4)
Mean duration of disease, years (± SD) 2.6 (± 1.8)
Gender
Male (%) 88 (44.7)
Female (%) 109 (55.3)
Race
Asian (%) 9 (4.6)
Black or African American (%) 14 (7.1)
Multiracial or Other (%) 5 (2.5)
White (%) 142 (72.1)
Unknown (%) 27 (13.7)
Ethnicity
Hispanic or Latino (%) 39 (19.8)
Not Hispanic or Latino (%) 155 (78.7)
Unknown Ethnic Group (%) 3 (1.5)
At diagnosis
Mean morning Cortisol level, mcg/dL (± SD) 20.4 (± 13.5)
Mean midnight Cortisol level, mcg/dL (± SD) 18.6 (± 13.2)
UFC, mcg/24H (± SD) 399 (± 1465.1)
Etiology of CS
Cushing Disease (%) 154 (78.2)
Ectopic ACTH production (%) 5 (2.5)
ACTH-independent CS (%) 38 (19.3)
Postoperative course
Cure (%) 142 (72.1)
No cure after surgery (%) 8 (4.1)
Recurrence (%) 13 (6.6)
No follow up (%) 34 (17.2)
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